Evidence map›Paper›PMID 28971146›Full record

ArticleeNeurologicalSci2017

Clinical and molecular correlates in fragile X premutation females.

Poonnada Jiraanont, Stefan R Sweha, Reem R AlOlaby, Marisol Silva, Hiu-Tung Tang, Blythe Durbin-Johnson, Andrea Schneider, Glenda M Espinal, Paul J Hagerman, Susan M Rivera and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eNeurologicalSci, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The Phenotypic Profile Associated With theFrontiers in psychiatry · 2021
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Poonnada JiraanontDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.
Stefan R SwehaDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.
Reem R AlOlabyDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.
Marisol SilvaDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.
Hiu-Tung TangDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.
Blythe Durbin-JohnsonDepartment of Public Health Sciences, School of Medicine, University of California at Davis, Davis, CA, USA.
Andrea SchneiderDepartment of Pediatrics, School of Medicine, University of California Davis, Davis, CA, USA.
Glenda M EspinalDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.
Paul J HagermanDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.
Susan M RiveraMIND Institute, University of California Davis Medical Center, Sacramento, CA, USA.
David HesslMIND Institute, University of California Davis Medical Center, Sacramento, CA, USA.
Randi J HagermanDepartment of Pediatrics, School of Medicine, University of California Davis, Davis, CA, USA.
Nuanchan ChutabhakdikulResearch Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakornpathom, Thailand.
Flora TassoneDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Davis, CA, USA.

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
GENOTYPE/PHENOTYPE RELATIONSHIPS IN FRAGILE X FAMILIESR01HD036071 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI PAUL J HAGERMAN, RANDI J. HAGERMAN · 1998 to 2026
$13.8M
Rodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ABBEDUTO, LEONARD J. · 2013 to 2019
$8.5M
Interdisciplinary Training for Autism Researchers(RMI)T32MH073124 · NIMH · UNIVERSITY OF CALIFORNIA DAVIS · PI Stephen Charles Noctor, Christine Wu Nordahl · 2004 to 2026
$6.8M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01MH078041 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HESSL, DAVID R, RIVERA, SUSAN M · 2007 to 2017
$5.4M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01NS110100 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAVID R HESSL, Susan M Rivera · 2018 to 2026
$5.4M
Epigenetic regulation of the FMR1 geneR01GM113929 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEDIN, FREDERIC LOUIS, HAGERMAN, PAUL J · 2015 to 2018
$1.9M
NCATS NIH HHS UL1 TR001860NICHD NIH HHS R01 HD036071NICHD NIH HHS U54 HD079125NIGMS NIH HHS R01 GM113929NIMH NIH HHS R01 MH078041NIMH NIH HHS T32 MH073124NINDS NIH HHS R01 NS110100
6 · The paper itself

Abstract

The prevalence of the fragile X premutation (55-200 CGG repeats) among the general population is relatively high, but there remains a lack of clear understanding of the links between molecular biomarkers and clinical outcomes. In this study we investigated the correlations between molecular measures (CGG repeat size,

Indexed as

Executive functionFREE2 methylationPremutation allelesPsychiatric problems

Identifiers

PMID28971146
PMCPMC5621595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.